Hammad

Landmark Paper: in 2012, J.P. Patel and colleagues reported in the NEJM a milestone comprehensive molecular analysis that continues to shape modern AML management haematologica.org/article/view/1…

Acute leukemia of ambiguous lineage: the known and the uncertain haematologica.org/article/view/1…

Azacytidine, our fantastic hypomethylating agent, used for treatment of MDS and AML, was discovered in 1964, and then fell into oblivion. Almost 40 years later it was FDA approved as the first effective MDS treatment. A 🧵about an unusual revival:

@sebas_arruarana @American_Heart That's great Hammad2286@gmail.com Regards

Great opportunity to be certified by the American Heart Association for free! In Project IMG we partnered with @American_Heart to earn the CPAHA (Certified Professional by AHA) which normally it’s $519 and we got it 100% complementary for our members and lasts 3 years and it’s also a boost for you CV! It is a professional certification for healthcare professionals to demonstrate expertise in specific areas like telehealth or digital health, helping to improve patient outcomes through standardized training and the integration of new technologies. To obtain your code, take this code and get certified please comment your email on this post: Important info: Exam must be scheduled by Dec 31, 2025!!

CONGRESS | #IACH | PRESENTATION Maria Helena Parrinello @Emmeaccapi, San Raffaele Hospital, presents a case study of a patient with cGvHD and new-onset dysphagia. Parrinello highlights the importance of long-term monitoring for detection of secondary malignancies after HSCT. Follow our live feed for more updates: loom.ly/-pymO8A Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #GvHD #GvHDsm #MedicalCongress

@TheIACH @Mohty_EBMT Thnx for the wonderful talk Is it possible to get the slides of this ppt?

𝗛𝗮𝗽𝗽𝗲𝗻𝗶𝗻𝗴 𝗧𝗢𝗗𝗔𝗬 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗳𝗼𝗿 𝗙𝗥𝗘𝗘 @Mohty_EBMT

4/4 In other words, KPC is one of the mechanisms by which certain CRE bacteria achieve carbapenem resistance. Not all CRE produce KPC; some may use other carbapenemase enzymes or different resistance mechanisms. KPC-producing CRE is a subset of CRE and is notably common in US

3/X - KPC (Klebsiella pneumoniae carbapenemase) is a specific enzyme produced by some CRE bacteria. KPC breaks down carbapenems, making these antibiotics ineffective against the bacteria.

1/X What is difference bw CRE and KPC microbes The key difference between CRE and KPC microbes lies in their definitions and relationship:

Response assessment in #AML

2/2 ❌ Resistant / Poor Responders: - Monocytic AML (M4/M5, esp. mature/secondary type) - TP53-mutated AML - FLT3-ITD / TKD mutations - RAS pathway mutations (NRAS, KRAS, PTPN11) - KMT2A (MLL) rearranged AML - Complex karyotype AML - Secondary AML from MDS/MPN #AML

📌 AML Response to Venetoclax (VEN) ✅ Good Responders: - NPM1-mutated AML - IDH1 / IDH2-mutated AML - RUNX1-mutated AML (some cases) - De novo AML without adverse genetics 1/2 #AML

@nihardesai89 @ASH_hematology @DrAkhilX @BrownJHM @VJHemOnc @MorphologyAmigo @VaqueraH_md @TheEBMT_Trainee @DrNikitaMehra @rudra09s025 @GonzaloBentoli1 Copper deficiency or Zinc toxicity

You are a pathologist reviewing the BM aspirate of a 64 yr old male with pancytopenia! You see this 👇🏽 Ddx? 📸 @ASH_hematology image bank

🧪 Thiotepa in Conditioning — MAC vs RIC ⸻ 🔥 Myeloablative Conditioning (MAC) •Thiotepa 10 mg/kg (single dose) OR 5 mg/kg ×2 (total 10 mg/kg) 💥 •Often combined with 🧬 Busulfan, Fludarabine, ATG, TBI •Goal = full marrow ablation 🦴❌ ⸻ 🌿 Reduced-Intensity Conditioning (RIC) •Thiotepa 5 mg/kg (single dose) OR 2.5 mg/kg ×2 (total 5 mg/kg) 🌱 •Combined with Fludarabine ± Melphalan/Treosulfan •Goal = immunosuppression > ablation (engraftment with less toxicity) ⸻ 📌 Key Pearl 👉 Dose intensity = main difference: 10 mg/kg = MAC 💥, 5 mg/kg = RIC 🌿 👉 Adjust per protocol, disease, age, comorbidity, donor type. #SOHO25 #BMT #Conditioning #Thiotepa #HCT

@faheema_hasan ETP ALL

Awesome catch 👍..can we interpret this flow now 🙃

54 year old gentleman with fever and lymphadenopathy. 📣📣Calling all HEMAT fanatics ! What does the morphology suggest ?#hemeonc #MedTwitter #leusm

@faheema_hasan High grade lymphoma in leukemic Phase

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China ashpublications.org/blood/article-… The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively. #HLH @BloodPortfolio

CD45 negative cells in Hematology Hodgkin Myeloma Mets Some cases of B-ALL #Haematology #Immunophenotyping